These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15736142)

  • 41. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Down the road to product analysis, step by step. Medical Alley's Cost-Effectiveness Task Force.
    Mater Manag Health Care; 1995 Sep; 4(9):24. PubMed ID: 10151136
    [No Abstract]   [Full Text] [Related]  

  • 43. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Application of stochastic multiattribute analysis to assessment of single walled carbon nanotube synthesis processes.
    Canis L; Linkov I; Seager TP
    Environ Sci Technol; 2010 Nov; 44(22):8704-11. PubMed ID: 20964398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple criteria decision analysis for health technology assessment.
    Thokala P; Duenas A
    Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A diagnostic advice system based on pathophysiological models of diseases.
    ter Burg WJ; Lucas P; ter Braak E
    Stud Health Technol Inform; 1999; 68():654-9. PubMed ID: 10724972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.
    Philips Z; Bojke L; Sculpher M; Claxton K; Golder S
    Pharmacoeconomics; 2006; 24(4):355-71. PubMed ID: 16605282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.
    Dakin HA; Devlin NJ; Odeyemi IA
    Health Policy; 2006 Aug; 77(3):352-67. PubMed ID: 16213624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring uncertainty in cost-effectiveness analysis.
    Claxton K
    Pharmacoeconomics; 2008; 26(9):781-98. PubMed ID: 18767898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care.
    Bujkiewicz S; Jones HE; Lai MC; Cooper NJ; Hawkins N; Squires H; Abrams KR; Spiegelhalter DJ; Sutton AJ
    Value Health; 2011; 14(5):768-76. PubMed ID: 21839417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
    Mullahy J
    Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321
    [No Abstract]   [Full Text] [Related]  

  • 54. Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
    Rothery C; Strong M; Koffijberg HE; Basu A; Ghabri S; Knies S; Murray JF; Sanders Schmidler GD; Steuten L; Fenwick E
    Value Health; 2020 Mar; 23(3):277-286. PubMed ID: 32197720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
    Forster M; Pertile P
    Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of Expert Judgement Across NICE Guidance-Making Programmes: A Review of Current Processes and Suitability of Existing Tools to Support the Use of Expert Elicitation.
    Peel A; Jenks M; Choudhury M; Lovett R; Rejon-Parrilla JC; Sims A; Craig J
    Appl Health Econ Health Policy; 2018 Dec; 16(6):819-836. PubMed ID: 30073485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
    Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
    Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence informed decision making: the use of "colloquial evidence" at nice.
    Sharma T; Choudhury M; Kaur B; Naidoo B; Garner S; Littlejohns P; Staniszewska S
    Int J Technol Assess Health Care; 2015 Jan; 31(3):138-46. PubMed ID: 25991028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrated analysis: combining risk and economic assessments while preserving the separation of powers.
    Williams RA; Thompson KM
    Risk Anal; 2004 Dec; 24(6):1613-23. PubMed ID: 15660616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
    Gafni A; Birch S; ;
    Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.